Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice by Tsai, Chia-Che et al.
© 2011 Tsai et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 2607–2619
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2607
OrIgINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S23834
Biodistribution and pharmacokinetics  
of 188re-liposomes and their comparative 
therapeutic efficacy with 5-fluorouracil  
in c26 colonic peritoneal carcinomatosis mice
chia-che Tsai1
chih-hsien chang1
Liang-cheng chen1
Ya-Jen chang1
Keng-Li Lan2
Yu-hsien Wu1
chin-Wei hsu1
I-hsiang Liu1
chung-Li ho1
Wan-chi Lee1
hsiao-chiang Ni1
Tsui-Jung chang1
gann Ting3
Te-Wei Lee1
1Institute of Nuclear energy  
research, Taoyuan, 2cancer center, 
Taipei Veterans general hospital, 
Taipei, 3National health research 
Institutes, Taipei, Taiwan, rOc
correspondence: Te-Wei Lee 
Institute of Nuclear energy research, 
1000 Wenhua road, chiaan Village, 
Lungtan, Taoyuan, Taiwan, rOc 
Tel +886 3 4711400 
Fax +886-3-4711416 
email twlee@iner.gov.tw
Background: Nanoliposomes are designed as carriers capable of packaging drugs through 
  passive targeting tumor sites by enhanced permeability and retention (EPR) effects. In the 
present study the biodistribution, pharmacokinetics, micro single-photon emission computed 
tomography (micro-SPECT/CT) image, dosimetry, and therapeutic efficacy of 188Re-labeled 
nanoliposomes (188Re-liposomes) in a C26 colonic peritoneal carcinomatosis mouse model 
were evaluated.
Methods: Colon carcinoma peritoneal metastatic BALB/c mice were intravenously administered 
188Re-liposomes. Biodistribution and micro-SPECT/CT imaging were performed to determine 
the drug profile and targeting efficiency of 188Re-liposomes. Pharmacokinetics study was 
described by a noncompartmental model. The OLINDA|EXM® computer program was used 
for the dosimetry evaluation. For therapeutic efficacy, the survival, tumor, and ascites   inhibition 
of mice after treatment with  188Re-liposomes and 5-fluorouracil (5-FU), respectively, were 
evaluated and compared.
Results: In biodistribution, the highest uptake of  188Re-liposomes in tumor tissues 
(7.91% ± 2.02% of the injected dose per gram of tissue [%ID/g]) and a high tumor to 
muscle ratio (25.8 ± 6.1) were observed at 24 hours after intravenous administration. The 
pharmacokinetics of  188Re-liposomes showed high circulation time and high bioavailability 
(mean residence time [MRT] = 19.2 hours, area under the curve [AUC] = 820.4%ID/g*h). 
Micro-SPECT/CT imaging of 188Re-liposomes showed a high uptake and targeting in ascites, 
liver, spleen, and tumor. The results were correlated with images from autoradiography and 
biodistribution data. Dosimetry study revealed that the  188Re-liposomes did not cause high 
absorbed doses in normal tissue but did in small tumors. Radiotherapeutics with 188Re-liposomes 
provided better survival time (increased by 34.6% of life span; P , 0.05), tumor and ascites 
inhibition (decreased by 63.4% and 83.3% at 7 days after treatment; P , 0.05) in mice compared 
with chemotherapeutics of 5-fluorouracil (5-FU).
Conclusion: The use of  188Re-liposomes for passively targeted tumor therapy had greater 
therapeutic effect than the currently clinically applied chemotherapeutics drug 5-FU in a colonic 
peritoneal carcinomatosis mouse model. This result suggests that 188Re-liposomes have potential 
benefit and are safe in treating peritoneal carcinomatasis of colon cancer.
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Introduction
Colorectal cancer is one of the most common types of cancer in men and women. 
Its prognosis depends on the extent of the disease and only about 40% of patients International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with colorectal cancers are diagnosed at the early stage.1 
At this stage, surgical tumor resection is the main method 
of treatment and the 5-year survival rate of patients can 
reach 90%. If the cancer has progressed, there is lymph node 
involvement and development of hematogenous metastases, 
so that prognosis becomes poor.2 Peritoneal dissemination 
is considered the terminal stage in colorectal cancer. 
“Peritoneal carcinomatosis” means extensive or widespread 
dissemination of tumor nodules inside the abdomen. Certain 
sites in the abdomen are more prone to implantation of tumor 
cells, including the greater omentum, the hepatic hilum, 
the mesentery, the pelvis, and the peritoneum covering the 
diaphragm.3,4 Peritoneal carcinomatosis is also the most 
common cause of malignant ascites; the production and 
leakage of fluid from the malignant cells causes exudation of 
extracellular fluid into the peritoneal cavity, in turn causing 
discomfort, pain, and symptoms that diminish the quality of 
life for cancer patients.5
The treatment of peritoneal or distant metastasis from 
colorectal cancer remains a challenging problem.2 For several 
decades, regimens based on 5-fluorouracil (5-FU) have been 
the first choice for primary or adjuvant chemotherapy for 
colorectal cancer.6,7 5-FU belongs to the family of drugs 
called “antimetabolites” and works through noncompetitive 
inhibition of thymidylate synthase. In clinical standard care 
for first-line therapy, patients with metastatic colorectal 
cancer receiving systemic chemotherapy of 5-FU and 
leucovorin have a median survival that is increased from 
approximately 6 months to about 12 months.7 In recent 
years, a number of new treatments have become available for 
patients with advanced colorectal cancer. The effectiveness 
of these drugs has been compared with that of 5-FU in clinical 
studies.2,8 However, no effective therapy for peritoneal 
metastasis is yet available, though novel agents remain under 
investigation. In preclinical drug development, 5-FU also 
serves as the comparative object to evaluate the anticancer 
efficacy for colon cancer.9,10
Several therapeutics based on nanoparticles have been suc-
cessfully introduced for cancer treatment. The first generation 
of nanoparticles is primarily based on liposomes and polymer-
drug conjugates.11 Nanoliposomes are double-membrane 
lipid vesicles capable of packaging drugs for various deliv-
ery applications. Nanopegylated liposomes can evade the 
reticuloendothelial system and remain in the circulation for 
prolonged periods, improving tumor targeting and efficacy 
in animal models. Nanopegylated liposomes provide passive 
targeting because of nanoliposome accumulation in tumors 
by means of the enhanced permeability and retention (EPR) 
effect through leaky tumor vasculature.12,13 Preclinical studies 
have shown that cytotoxic agents entrapped in pegylated lipo-
somes tend to accumulate in tumors.14,15 A prominent example 
is pegylated liposomal doxorubicin, which has been applied in 
patients with acquired immune deficiency syndrome–related 
Kaposi’s sarcoma (ARKS), as well as ovarian, breast, and 
prostate carcinomas.16–18
Preclinical studies of tumor therapy with radionuclide-
liposome conjugates or liposome-mediated radiotherapeutics 
have been reported.19 Rhenium-188 (188Re) is a radionuclide 
used for imaging and therapeutic dual applications due 
to its short physical half-life of 16.9 hours with 155 keV 
gamma emissions for imaging, and its 2.12 MeV β emission 
with a maximum tissue penetration range of 11 mm for 
tumor therapeutics. In addition, 188Re can be obtained from 
commercial nuclear generators, which makes it convenient 
for routine research and clinical use.20
In this study, the biodistribution, pharmacokinetics, 
and micro single-photon emission computed tomography 
(micro-SPECT/CT) imaging of intravenous injection of 
188Re-liposomes were investigated in a C26 colonic peritoneal 
carcinomatosis mouse model. The therapeutic efficacy of 
188Re-liposomes was compared with that of 5-FU. The experi-
mental goals were to demonstrate the potential applications 
of nanotargeted  188Re-liposomes via an intravenous route 
for internal radiotherapy of peritoneal carcinomatosis and 
ascites.
Materials and methods
Materials
Pegylated liposomes (Nano-X) were provided by Taiwan 
Liposome Company (Taipei, Taiwan). The tungsten-188 
(188 W)/188Re generator was purchased from Oak Ridge National 
Laboratory (Oak Ridge, TN). Elution of the 188 W/188Re generator 
with normal saline provided solutions of carrier-free 188Re as 
sodium perrhenate (NaReO4). N,N-bis(2-mercaptoethyl)-N′,N′-
diethylethylenediamine (BMEDA) were purchased from ABX 
(Radeberg, Germany). The C26 murine colon carcinoma cell 
line was obtained from the American Type Culture Collection 
(Manassas, VA). Stannous chloride (SnCl2) was purchased 
from MERCK (Darmstadt, Germany). The PD-10 column was 
purchased from GE Healthcare (Uppsala, Sweden). All other 
chemicals were purchased from MERCK.
cell culture and animal tumor ascites 
model
C26 murine colon carcinoma cell line was obtained 
from the American Type Culture Collection (  Manassas). International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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It  was  grown  in  Roswell  Park  Memorial  Institute 
  medium–1640 supplemented with 10% (v/v) fetal bovine 
serum, 2 mM L-glutamine at 37°C in 5% CO2. Male BALB/c 
mice were obtained from the National Laboratory Animal 
Center, Taipei, Taiwan. Mice were housed in a controlled 
environment, with food and water provided ad libitum. 
One hundred and seventy-one mice (6–8 weeks old) were 
inoculated intraperitoneally with 2 × 105 C26 cells in 500 µL 
phosphate-buffered saline. Mice were sacrificed by CO2 
asphyxiation at the desired time points after tumor   inoculation. 
The abdominal cavity was carefully inspected and all 
ascites and tumor nodules were meticulously collected and 
weighed. Animal protocols were approved by the Institutional 
Animal Care and Use Committee at the Institute of Nuclear 
Energy Research, Taiwan.
Preparation of 188re-BMeDA-labeled 
pegylated liposomes (188re-liposomes)
The pegylated liposomes (Nano-X) were prepared according to 
the method described by Tseng et al.21 The lipid compositions 
of liposome contain hydrogen soybean phosphatidylchloine 
(HSPC), cholesterol, polyethylene glycol-(1,2-distearoyl-sn-
glycero-3-phosphatidylethanolamine) (PEG-DSPE; molar 
ratio 3:2:0.3) and ammonium sulfate solution with [250 mM 
(NH4)2SO4, pH 5.0] in the inner water phase. Pegylated 
nanoliposomes have an average particle size of about 
82.59 nm and contain 13.16 µmole/mL phospholipids.
The method for radiolabeling BMEDA with 188Re 
was as has been previously described.22 Briefly, BMEDA 
(ABX), stannous chloride was used as the reductant and 
glucoheptonate (Sigma-Aldrich, St Louis, MO) was used 
as an intermediate ligand to make 188Re-SNS/S complexes. 
Five milligrams of BMEDA were pipetted into a fresh vial. 
A volume of 0.5 mL of 0.17 mol/L glucohepatonate dis-
solved in a 10% acetate solution was added, followed by the 
addition of 120 µL (10 µg/µL) of stannous chloride. After 
flushing the solution with N2 gas, highly specific activity 
of 188Re-sodium perrhenate was added. The vial was sealed 
and heated in an 80°C water bath for 1 hour. The labeling 
efficiency of  188Re-BMEDA complexes was analyzed by 
silica gel–impregnated glass fiber sheets using normal saline 
as the developer.
The Nano-X pegylated liposomes (1 mL) were added to 
the 188Re-BMEDA (50–250 MBq) solution and incubated at 
60°C for 30 minutes. The 188Re-liposomes were separated 
from free 188Re-BMEDA using a PD-10 column eluted with 
normal saline. Each 0.5 mL fraction was collected into a tube. 
The opacity of pegylated liposomes was used to visually 
monitor the collection of the 188Re-liposomes. The labeling 
efficiency was determined using the activity in pegylated 
liposomes after separation, divided by the total activity 
before separation.
Biodistribution and pharmacokinetic 
studies
Thirty-five C26 colon peritoneal metastatic carcinoma-
bearing mice (22–26 g, average weight 24.6 g) received 
an intravenous injection of 3.7 MBq/200 μL of  188Re-
liposomes with 0.88 µmol phospholipid for biodistribution 
and pharmacokinetic studies. Mice were kept on a 12-hour 
day/night cycle and had free access to food and water. 
For biodistribution study, 30 mice were sacrificed by CO2 
asphyxiation, five mice each at 1, 4, 16, 24, 48, and 72 hours 
after administration. At each time point, the organs of interest 
were sampled and whole organs collected where possible. 
The samples were rinsed in saline, blotted dry, weighed, 
and then counted using a Packard Cobra II Auto-Gamma 
(PerkinElmer, Inc, Waltham, MA) counter. Samples of the 
injection of 188Re-liposomes were used as decay correction 
standards. Data were expressed as percent of the injected 
dose (ID) per gram of tissue (%ID/g).
For pharmacokinetics, blood samples of 20 to 100 µL 
were collected at 0.083 (5 minutes), 0.5, 1, 4, 16, 24, 48, 72, 
120, and 168 hours from five mice via heart puncture after 
intravenous injection of 188Re-liposomes (20 µL at 0.083, 
0.5, 1, 4, 16, 24 hours; 50 µL at 48, 72, 120 hours; 100 µL 
at 168 hours). Concentrations of radioactivity in the blood 
were expressed as %ID/mL. Pharmacokinetic parameters 
were determined using WinNonlin (v 5.0.1; Pharsight 
Corp, Mountain View, CA) software. Noncompartmental 
analysis model 200 (extravascular input) was used with 
the Log/linear trapezoidal rule. Parameters, including 
terminal half-life (T1/2λz), Tmax, Cmax, total body clearance 
(Cl) and area under the curve (AUC) were determined. 
Pharmacokinetic parameters associated with the terminal 
phase were calculated using the best-fit method to estimate 
the terminal half-life.
Micro-sPecT/cT imaging and whole-
body autoradiography (WBAr)
For micro-SPECT/CT imaging, three mice received an 
intravenous injection of 12.95 MBq/200 µL of 188Re-liposomes 
and 0.88 µmol phospholipid. The mice were anesthetized 
with 1.5% isoflurine (positioned prone in the scanner) 
and received micro-SPECT/CT imaging at 72 hours after 
intravenous injection. SPECT and CT images were acquired International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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using a micro-SPECT/CT scanner (X-SPECT/CT, Gamma 
Medica, Northridge, CA). The SPECT images were acquired 
using a parallel hole collimator, with the center of the field 
of view (FOV) focused on the abdomen of each mouse. The 
radius of rotation was 1 cm with an FOV of 1.37 cm. The 
imaging was accomplished using 64 projections at 60 seconds 
per projection. SPECT imaging was followed by CT image 
acquisition (X-ray source: 50 kVp, 0.4 mA; 256 projections). 
The software provided with the X-SPECT/CT scanner 
was used for the SPECT and CT image reconstruction 
including the SPECT/CT image fusion. SPECT images were 
reconstructed to produce image sizes of 56 × 56 × 56 pixels 
with an image resolution of 1.2 mm. CT images were also 
reconstructed in image sizes of 512 × 512 × 512 pixels with 
0.15 mm image resolution.
The procedure for WBAR has been previously described. 
Mice were sacrificed by CO2 euthanasia at 72 hours after 
micro-SPECT/CT imaging and were immediately dipped into 
liquid nitrogen. The frozen carcasses were then embedded with 
2.5% carboxymethyl cellulose and the frozen carboxymethyl 
cellulose block was attached to the sample stage in the cryo-
chamber (−20°C). After resting for 2 hours, the frozen sample 
was then sectioned (into slices 40 µm thick) using a cryomi-
crotome (CM 3600; Leica Microsystems GmbH, Wetzlar, 
Germany) at –20°C. These samples were placed in contact 
with an imaging plate (BAS-MS 2040; Fuji Photo Film Co) 
for 5 days. After completing the exposure, the imaging plate 
was analyzed with a FLA-5100 (Fuji Photo Film Co) reader 
and the Multi Gauge v 3.0 (Fuji Photo Film Co) software.
Absorbed radiation dose calculations
To estimate mean absorbed doses in humans, the relative 
organ mass scaling method was used. The mean absorbed 
dose in various tissues is derived from the radionuclide 
concentration in tissues/organs of interest, assuming a 
homogeneous distribution of the radionuclide within any 
source region. The calculated mean value of %IA/g for the 
organs in mice was extrapolated to uptake in organs of a 
70 kg adult using the formula:
[(%IA/gorgan)animal × (kgTBweight)animal] × (gorgan/kgTBweight)human  
  = (%IA/organ)human.
The extrapolated values (%IA) in human organs at 1, 4, 16, 
24, 48, and 72 hours were fitted with exponential biokinetic 
models and integrated to obtain the number of disintegrations 
in the source organs; this information was entered into the 
OLINDA|EXM® (v 1.0; Vanderbilt University, Nashville, 
TN) program. The integrals (MBq-s) for 14 organs, including 
heart contents (blood), brain, muscle, bone, heart, lung, testes, 
spleen, pancreas, kidneys, liver, stomach, small intestine, 
lower intestine, and remainder of the body, were evaluated 
and used for the dosimetry evaluation.
For excretion study, mice were kept in metabolic cages 
and urine and feces were collected at various time intervals. 
Cumulative excretion was calculated as %ID. All feces and 
urine during the study period were collected for   estimation 
of fraction and biological half-life of elimination. Cumulative 
excretion curves (urine and feces) were fitted from 0 to 
168 hours with a function of the form: ft = f*(1−exp(−λ*t)) 
using SigmaPlot® (Systat Software Inc, San Jose, CA) 
software. The ICRP 30 GI Model and Voiding Urinary Bladder 
Model in OLINDA|EXM were used to estimate the number of 
disintegrations occurring in the excretory organs. For gastro-
intestinal (GI) excretion, the fraction (f) entering at the small 
intestine was entered into the GI model module. For bladder 
excretion, the fraction passing bladder and biological half-life 
was entered in the Bladder Model. Activity in the remainder 
of the body was defined as the total injected activity minus the 
total excretion at any time (urine and feces) and activity in all 
individual organs evaluated. This activity was assumed to be 
uniformly distributed in the “remainder of the body.”
To estimate the absorbed dose for different tumor sizes 
ranging from 0.5 to 300 g mass, the mean value of total 
tumor nodules (%IA/g) obtained by mouse biodistribution 
study was directly fitted with exponential models to calculate 
the number of disintegrations, which again was input into 
OLINDA|EXM using the unit density sphere model.
Maximum tolerated dose
The maximum tolerated dose (MTD) was defined as the 
  activity dose below the dose resulting in either the death of any 
animal in groups of five animals or a body weight loss of more 
than 20%.23,24 The toxicity radio-therapeutic 188Re-liposome 
and chemo-therapeutic 5-FU was monitored by MTD study. 
Fifty male BALB/c mice were randomly grouped into cages of 
five mice (each mouse weighing 24.3 g on average). Mice were 
given 14.8, 22.2, 29.6, 37, and 44.4 MBq of 188Re-liposomes 
and 90, 120, 150, 180, and 210 mg/kg of 5-FU in 200 µL by 
single intravenous injection, respectively. Mice were weighed 
twice per week, and the survival rate of the mice was recorded 
daily. The drug-induced toxicities (lethality and body weight 
loss) were determined for a minimum of 4 weeks.
Therapeutic efficacy studies
At 7 days after intraperitoneal tumor cell inoculation, three 
groups of ten mice (each weighing 24.1 g on average) received International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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intravenous injections of 200 µL 188Re-liposomes (80% MTD, 
29.6 MBq, and 0.88 µmol phospholipid), 144 mg/kg (80% 
MTD) 5-FU dissolved in 200 µL normal saline, and 200 µL 
normal saline (control) respectively. Mice were checked for 
survival every day, and body weight was measured twice a 
week. The abdominal cavity was conscientiously inspected. 
The median survival time was carefully estimated using the 
Kaplan–Meier method of survival analysis for each treatment 
group. A Log-rank test was used to compare survival between 
treatment groups. The median survival time presented in the 
efficacy studies is calculated as the smallest survival time for 
which the survivor function is equal to 0.5.
To investigate the effects of  188Re-liposomes on the 
tumor growth and ascites formation, 16 mice per group were 
intravenously treated with 188Re-liposomes, 5-FU, and normal 
saline, respectively (doses as described above) at 7 days 
after intraperitoneal tumor cell inoculation. Four mice per 
group were sacrificed by CO2 asphyxiation at 7, 9, 12, and 
14 days after tumor inoculation. The abdominal cavity was 
conscientiously inspected. All ascites and tumor nodules 
were meticulously collected and weighed.
statistical analysis
Data were expressed as mean ± standard error of the mean. 
SPSS 11 (SPSS Inc, Armonk, NY) software was used to per-
form statistical analysis, and the survival data were estimated 
by the Kaplan–Meier method and compared by Log-rank test. 
Values of P , 0.05 were considered significant. The uptake 
value of drug in a tumor was compared by t-test. Values of 
P , 0.05 were considered significant.
Results
Biodistribution studies of 188re-liposomes
The biodistribution of  188Re-liposomes in the peritoneal 
carcinomatosis mouse model was studied at 1, 4, 24, 48, 
and 72 hours after intravenous injection and the results 
are summarized in Table 1. The 188Re-liposomes in blood 
circulation were still at a high level of 11.2% ± 1.17% ID/g 
at 24 hours postinjection. Most normal organs reached the 
maximum levels at 4 hours postinjection. Uptakes of 188Re-
liposomes in normal organs were observed mainly in the 
spleen, kidney, and liver. Radioactivity in spleen, kidney, 
and liver reached the highest levels of 10.4% ± 0.7% ID/g, 
9.98% ± 0.45% ID/g, and 10.2% ± 0.57% ID/g,   respectively. 
After systemic administration of 188Re-liposomes, radioac-
tivity localized in ascites appeared at 1 hour and was main-
tained at higher levels from 15.5% ± 0.74% ID/g at 4 hours 
to 10.8% ± 1.27% ID/g at 24 hours. The radioactivity in 
total tumor nodules rapidly accumulated to a high level of 
7.23% ± 1.39% ID/g at 4 hours and progressively achieved 
a maximum of 7.91% ± 2.02% ID/g at 24 hours after intra-
venous administration of the 188Re-liposomes. According to 
the anatomical studies, C26 tumor nodules spread through-
out the peritoneal cavity, with most nodules appearing 
around the greater omentum, mesentery, diaphragm, and 
liver hilum at 10 days after inoculation. The uptakes of 
188Re-liposomes in tumor nodules collected from greater 
omentum, mesentery, and diaphragm were similar. Although 
the radioactivity in tumor nodules sampled from liver hilum 
was slightly less, there was no significant difference com-
pared with levels from other implanted sites. The Tu to Mu 
ratio of 188Re-liposomes reached 30.6 ± 9.3 and 25.8 ± 6.1 
at 16 hours and 24 hours after injection, respectively. Very 
low levels of 188Re-liposome uptake were noted in organs 
of the central nervous and musculoskeletal systems.
Pharmacokinetics studies of  
188re-liposome
The radioactivity–time curves from blood versus time 
points after intravenous injection of  188Re-liposome are 
shown in Figure 1. Pharmacokinetic parameters in the 
peritoneal carcinomatosis mice model were estimated using 
WinNolin and a noncompartmental model (Rsq = 0.9554), as 
summarized in Table 2. The maximum radioactivity (Cmax) 
in blood was determined as 47.1% ID/mL at 10 minutes 
for 188Re-liposomes, which was also the Tmax in the blood. 
The terminal half-life (T1/2λz) of  188Re-liposomes was 
16.3 hours after intravenous injection. The AUCo→∞ of 188Re-
liposomes was 820.4% ID/g*h. The Cl of 188Re-liposomes 
was 0.12 mL/h. The mean residence time (MRTo→∞) of 
188Re-liposomes was 19.2 hours. These results revealed that 
188Re-liposomes exhibited high bioavailability and that long 
circulation of nanoliposome therapeutics was achieved in 
the peritoneal carcinomatosis mice model.
Micro-sPecT/cT imaging and WBAr
To confirm the specific targeting of tumor sites and ascites of 
188Re-liposomes, microSPECT/CT imaging and WBAR were 
performed. The micro-SPECT/CT images of C26 tumor and 
ascites-bearing mice (on day 7 after tumor inoculation) acquired 
at different times after intravenous injection of 188Re-liposomes 
are shown in Figure 2A. 188Re-liposomes showed slow blood 
clearances and maintained a relatively higher activity in the 
abdominal cavity before 24 hours. Micro-SPECT/CT images 
showed a high uptake and targeting of  188Re-liposomes in 
ascites and also in the tumor, liver, and feces. WBAR was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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performed followed by the Micro-SPECT/CT scanning at 
72 hours. The WBAR image also confirmed the tumor target-
ing of microSPECT/CT results as shown in Figure 2B, which 
is consistent with the biodistribution data (Table 1).
Tissue radiation dose calculations
The radiation-absorbed dose projections for administration 
of 188Re-liposomes to humans, determined from the residence 
times in mice, are shown in Table 3. The fractions of the 
188Re-liposomes excreted in the urinary and GI tract derived 
from accumulative urine and feces were 12% and 48% ID, 
  respectively. That total excretion was 60% ID and was mostly 
through feces suggests the importance of hepatobiliary excretion 
for 188Re-liposomes. Lower doses were found, however, in other 
important therapy-limiting normal tissues such as the heart, lungs, 
liver, kidneys, and red marrow with values of 0.40 mSv/MBq, 
0.17 mSv/MBq, 0.24 mSv/MBq, 0.20 mSv/MBq, and 
0.04 mSv/MBq, respectively. The effective dose appears to 
Table 1 Biodistribution of 188re-liposome after intravenous injection in c26 colonic peritoneal carcinomatosis mice
(%ID/g) 1 hour 4 hours 16 hours 24 hours 48 hours 72 hours
Whole blood 41.1 ± 0.32 36.1 ± 2.25 12.6 ± 0.45 11.2 ± 1.17 3.35 ± 0.81 1.43 ± 0.14
Brain 0.91 ± 0.06 0.68 ± 0.09 0.29 ± 0.01 0.27 ± 0.02 0.10 ± 0.02 0.05 ± 0.01
skin 0.71 ± 0.07 0.87 ± 0.14 0.70 ± 0.15 0.80 ± 0.14 0.34 ± 0.06 0.44 ± 0.12
Muscle 0.39 ± 0.04 0.49 ± 0.13 0.26 ± 0.05 0.20 ± 0.04 0.11 ± 0.03 0.06 ± 0.01
Bone 2.06 ± 0.16 2.14 ± 0.19 1.04 ± 0.04 0.99 ± 0.05 0.35 ± 0.07 0.27 ± 0.06
spleen 9.25 ± 0.37 10.4 ± 0.70 7.47 ± 0.35 7.63 ± 0.64 2.18 ± 1.05 1.41 ± 0.14
small intestine 2.63 ± 0.55 3.98 ± 1.05 4.33 ± 1.28 4.70 ± 0.49 1.53 ± 0.66 0.78 ± 0.28
Large intestine 1.01 ± 0.11 1.39 ± 0.23 0.66 ± 0.26 1.01 ± 0.23 0.65 ± 0.12 0.36 ± 0.02
Kidney 9.24 ± 0.35 9.98 ± 0.45 4.16 ± 0.08 4.99 ± 0.79 1.56 ± 0.37 0.82 ± 0.04
Lung 7.80 ± 0.24 8.82 ± 0.71 3.15 ± 0.47 3.28 ± 0.39 1.21 ± 0.29 1.17 ± 0.44
heart 3.57 ± 0.31 3.38 ± 0.20 1.47 ± 0.02 1.72 ± 0.15 0.65 ± 0.14 0.38 ± 0.04
Liver 9.63 ± 0.37 10.2 ± 0.57 6.60 ± 0.87 5.25 ± 1.65 1.99 ± 0.79 1.13 ± 0.41
Bladder 1.25 ± 0.24 1.43 ± 0.27 0.84 ± 0.15 0.83 ± 0.09 0.36 ± 0.04 0.36 ± 0.02
Pancreas 1.79 ± 0.33 2.32 ± 0.15 1.10 ± 0.10 0.56 ± 0.36 0.23 ± 0.08 0.16 ± 0.04
stomach 1.38 ± 0.03 1.70 ± 0.12 1.75 ± 0.10 2.23 ± 0.35 0.80 ± 0.17 0.76 ± 0.22
Testes 0.74 ± 0.09 0.66 ± 0.04 0.50 ± 0.10 0.42 ± 0.07 0.22 ± 0.02 0.12 ± 0.00
Ascites 4.33 ± 0.54 15.5 ± 0.74 14.3 ± 0.69 10.8 ± 1.27 3.87 ± 0.86 1.61 ± 0.23
Metastases-1a 4.92 ± 0.51 8.49 ± 1.70 7.88 ± 0.68 8.67 ± 2.13 3.35 ± 0.84 0.85 ± 0.11
Metastases-2b 4.80 ± 1.11 3.40 ± 1.54 6.51 ± 0.37 3.69 ± 1.00 1.77 ± 0.45 1.06 ± 0.36
Metastases-3c 5.51 ± 2.07 7.75 ± 1.12 5.02 ± 0.62 7.41 ± 2.78 0.68 ± 0.33 0.76 ± 0.10
Total tumor 5.05 ± 0.47 7.23 ± 1.39 7.36 ± 0.32 7.91 ± 2.02 3.26 ± 0.86 0.85 ± 0.11
Tu/Mu 13.8 ± 1.41 22.5 ± 6.29 30.6 ± 9.37 25.8 ± 6.11 25.9 ± 4.68 17.3 ± 5.26
Notes: Data were expressed as a percentage of injected dose per gram (%ID/g ± standard error of the mean, n = 5 at each time point); ametastases-1: tumor nodules in 
greater omentum, perisplenic, and mesentery; bmetastases-2: in liver hilum; cmetastases-3: in diaphragm. 
Abbreviations: Tu, tumor; Mu, muscle.
Table  2  Pharmacokinetic  parameters  of  188re-liposome 
uptake  after  intravenous  injection  in  c26  colonic  peritoneal 
carcinomatosis mice
Parameter 188Re-liposomes
T½λz (h) 16.3
Tmax (h) 0.16
cmax (%ID/g) 47.1
cl (mL/h) 0.12
AUc(0→168) (%ID/g*h) 818.8
AUc(0→∞) (%ID/g*h) 820.4
MrT(0→∞) (h) 19.2
Notes: Values were calculated by mean of data (n = 5) using WinNonlin (v 5.0.1; 
Pharsight corp, Mountain View, cA) for a noncompartmental model. 
Abbreviations: T max, Time to achieve maximum concentration; Cmax, maximum 
plasma concentration; Cl, clearance; %ID/g, percentage of the injected dose per 
gram of tissue; AUC(0→∞), area under the tissue concentration–time curve from   
0 h to infinity; MRT, mean residence time.
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Figure 1 radioactivity–time curve of 188re-liposomes in blood. 
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Figure 2 (A) The micro single-photon emission computed tomography (micro-sPecT/cT) of 188re-liposome-treated c26 peritoneal metastatic tumor-bearing mice. The 
188Re-liposomes, containing 12.95 MBq of 188Re, were administered to each mouse by intravenous injection. Micro-SPECT images were acquired at 1, 4, 24, 48, and 72 hours 
after injection. (B) The whole-body autoradiography image was followed by micro-SPECT image acquisition at 72 hours after 188re-liposome injection, with the animal in the 
same position. Tumor nodules are indicated by arrows. 
Abbreviations: Li, liver; As, ascites; He, heart; Fe, feces; Te, testis; Bl, bladder.
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be approximately 0.80 mSv/MBq. Tumor radiation absorbed 
dose calculations are shown in Table 4. The unit density sphere 
model was used for calculation. Results revealed significantly 
greater absorption in tumor tissue than in normal organs. For a 
10 g tumor, the estimated absorbed dose was 65.7 mSv/MBq.
Therapeutic efficacy studies
In MTD study, the maximum dose with weight loss ,20% of 
188Re-liposomes and 5-FU was determined to be 37 MBq and 
180 mg/kg, respectively. In therapeutic efficacy studies, the 80% 
MTD of each drug was administered in each treatment group. 
Table 3 summarizes the therapeutic efficacy for each group 
receiving different treatments at 7 days after tumor inoculation. 
The survival curves for different treatment groups are shown in 
a Kaplan–Meier plot in Figure 3. Mice were treated at 7 days 
after tumor inoculation (n = 10 for each group). The median 
survival time for the control mice, who received normal saline, 
was 24.3 days (Table 5). The median survival times for the mice 
treated with 188Re-liposomes (29.6 MBq) and 5-FU (144 mg/kg) 
were 32.8 and 26.7 days, respectively. The results of the median 
survival time of the radiotherapeutics of  188Re-liposomes 
were statistically different from the chemotherapeutics of 
5-FU (P = 0.03). The therapeutic studies demonstrated better 
survival time and therapeutic efficacy for mice who received 
intravenously administered 188Re-liposomes. The P values for 
the differences among the survival curves of the various treat-
ment groups are shown in Table 5.
Tumor and ascites inhibition studies
The first macroscopic C26 tumor deposits in the peritoneal 
cavity were observed 5 days after intraperitoneal inoculation. 
Tumor deposits were small (1–3 mm in diameter) and mostly 
located in the upper abdomen in the great omentum and 
adjacent to the spleen. At 7–10 days after tumor inoculation, 
C26 tumor nodules had formed throughout the peritoneal 
cavity, with most nodules appearing in the great omentum, 
liver hilum, mesenterium, and diaphragm; ascites also 
formed. All visible tumor nodules and ascites were sampled 
and weighed during postmortem examination. The weights 
of the tumors and ascites are presented as the initial weights 
at 7 days after tumor inoculation for different groups. After 
188Re-liposomes and 5-FU were administered at 7 days after 
tumor inoculation, significantly large inhibitions of hemor-
rhagic ascites formation and tumor growth were observed International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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in the 188Re-liposome-treated group in comparison with the 
5-FU at 9–14 days (ascites: decrease of 83.3% and 44.9% at 
14 days for 188Re-liposome-treated group and 5-FU-treated 
group, respectively; tumor: decrease of 63.4% and 9.1% at 
14 days, respectively; P , 0.05) (Figure 4). To address the 
inhibition property of  188Re-liposomes in different meta-
static sites, tumor nodules were precisely sampled from the 
greater omentum, mesentery, liver hilum, and diaphragm. 
188Re-liposomes had significantly inhibited tumor growths in 
these implanted sites. Moreover, in comparison with 5-FU, 
188Re-liposomes demonstrated greater inhibition of the tumor 
growths in mesentery and liver hilum (mesentery: decrease of 
61.3% and 12.8% at 14 days for 188Re-liposome-treated group 
and 5-FU-treated group, respectively; liver hilum: decrease 
of 87.1% and 5.9% at 14 days, respectively; P , 0.05) 
(Figure 5). These results demonstrate better therapeutic 
efficacy in the inhibition of the progression in peritoneal 
carcinomatosis for mice that received intravenously admin-
istered 188Re-liposomes.
Discussion
Most cases with peritoneal carcionomatosis have no sat-
isfactory response to systemic chemotherapy.8 The main 
reason for this lack of success is that cytostatic drugs admin-
istrated intravenously do not affect tumors of peritoneal 
metastases with a sufficiently high concentration.25 Little 
previous research has evaluated the therapeutic efficacy of 
radionuclide-conjugated liposomes administered intrave-
nously in advanced metastatic colorectal cancer. Colorectal 
cancer frequently gives rise to the intraperitoneal spread 
of tumor cells and multiple metastatic tumor nodules are a 
result of peritoneal carcinomatosis. Initially, these nodules 
are small volume, with marked neovascularization in the 
infiltrate sites.26 The tumor-associated vascularization with 
high permeability is favorable for targeting by liposomal 
drugs by EPR effect. Therefore, ascertaining the efficacy of 
passively nanotargeted 188Re-liposomes via the intravenous 
route in peritoneal carcinomatosis of colorectal origin was 
worthwhile.
Biodistribution results confirmed the significantly high 
uptake in tumor tissues and that long blood circulation 
favored the use of 188Re-liposomes by systemic route in treat-
ing peritoneal carcinomatosis. In the authors’   previous report, 
the biodistribution, and pharmacokinetics of intraperitoneal 
injected  188Re-liposomes in a peritoneal carcinomatosis 
mouse model were studied.27,28 Compared with the current 
results, both administration routes exhibited prolonged 
retention of 188Re-liposomes within the ascites and tumors. 
In addition, they achieved the highest uptake of radioactivity 
in tumor tissues at 24-hours postinjection with a similar level 
(7.91% ± 2.02% intravenous ID/g versus 6.57% ± 1.71% 
intraperitoneal ID/g). However, intravenous injection of 
188Re-liposomes resulted in faster accumulation in tumor 
tissues than intraperitoneal injection: 7.23 ± 1.39 ID/g and 
3.34 ± 1.24 ID/g at 4 hours after injection, respectively. 
The level of radioactivity of 188Re-liposomes in blood was 
Table 3 radiation dose estimates for 188re-liposome in humans
Organ Estimated dose (mSv ⋅ MBq–1)*
Adrenals 5.75E-02
Brain 1.51E-02
Breasts 5.54E-02
gallbladder wall 6.26e-02
LLI wall 5.78E000
small intestine 1.05E000
stomach wall 7.68e-02
ULI wall 3.85E000
heart wall 4.02e-01
Kidneys 1.99e-01
Liver 2.40e-01
Lungs 1.65E-01
Muscle 1.35E-02
Ovaries 7.00e-02
Pancreas 4.39e-02
red marrow 4.20e-02
Osteogenic cells 1.49e-01
skin 5.51E-02
spleen 2.58E-01
Testes 1.96e-02
Thymus 5.63E-02
Thyroid 5.53E-02
Urinary bladder wall 1.69e-01
Uterus 6.34e-02
Total body 1.10e-01
effective dose 7.98e-01
Notes: *radiation-absorbed dose projections in humans were determined from 
residence  times  for  188re-liposomes  in  mice  bearing  c26  peritoneal  metastatic 
tumor and were calculated by use of OLINDA|eXM® (v 1.0; Vanderbilt University, 
Nashville, TN). 
Abbreviations: LLI, lower large intestine; ULI, upper large intestine.
Table 4 Absorbed doses of  188re-liposomes in sphere tumor 
derived from c26 peritoneal metastatic tumor
Sphere Mass (g) Estimated dose (mSv . MBq–1)*
0.5 1110
1 588
4 159
10 65.7
40 17.0
100 6.91
300 2.34
Notes: radiation-absorbed dose projections in  humans were  determined from 
residence  times  for  188re-liposomes  in  mice  bearing  c26  peritoneal  metastatic 
tumors and were calculated using OLINDA|eXM® (v 1.0; Vanderbilt University, 
Nashville, TN).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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maintained at relatively steady high levels for 24 hours after 
intravenous injection (Table 1).
It was noticed that after the redistribution of systemic 
circulation, more than 10% ID/g was recovered in the ascitic 
fluid over 4–24 hours. The presence of intravenous-injected 
188Re-liposomes in the peritoneal cavity may be associated 
with increased permeability of the tumor and peritoneal 
microvasculature. Previous studies with ascitic tumors dem-
onstrate a steady extravasation process of liposomes into 
the ascitic fluid with gradual release of the drug followed 
by drug diffusion into the ascitic cellular compartment.29,30 
This accumulation process has been shown to be related 
to the characteristics of the liposomes: small liposomes 
(with mean diameters of approximately 100 nm) achieve 
efficient accumulation in the peritoneal cavity in ascitic, 
tumor-bearing animals after intravenous injection.29 
The authors’ results suggest that the peritoneal cavity 
serves as an appropriate extravascular site for the passive 
targeting of 188Re-liposomes in peritoneal carcinomatosis. 
188Re-liposomes intravenously administered not only rap-
idly target tumor tissues by EPR effect but also provide an 
extravasated pool of highly   concentrated 188Re-liposomes 
surrounding the tumor nodules. The prolonged exposure 
of tumor to  188Re-liposomes by both mechanisms may 
account for the superior therapeutic effect observed in the 
experiments reported here.
In the authors’ previous studies, the biodistribution and 
pharmacokinetic properties of unencapsulated 188Re-BMEDA 
had been evaluated in a mouse model with C26 colon solid 
tumor and peritoneal carcinomatosis, respectively.22,27 
The results showed no evidence for the accumulation of 
188Re-BMEDA in tumors or in any normal organs. The 
fast blood clearance and excretion of 188Re-BMEDA were 
observed. Compared with the present study, 188Re-liposomes 
exhibited significant targeting and retention in the tumor. 
Pharmacokinetic study showed the slow clearance rate 
of  188Re-liposomes and the AUC was 4.7-fold greater 
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Figure 3 Kaplan–Meier survival curves for mice bearing c26 peritoneal metastatic tumor after administration of 188Re-liposomes (29.6 MBq,  ), 5-FU (144 mg/kg,  ), and 
normal saline (•) by single intravenous injection. Mice were treated 7 days after tumor inoculation. 
Note: n = 10 for each group.
Table 5 Comparative therapeutic efficacy of different treatments 
at 7 days after intraperitoneal c26 peritoneal metastatic tumor 
inoculation
Group Median  
survival time (d)
% ILSa Significance 
P value
188re-liposome 
(29.6 MBq) 
5-FU (144 mg/kg)
32.8 
 
26.7
34.6 
 
9.6
0.0006b, 0.03c 
 
0.001b
Normal saline 
(control)
24.3 – –
Notes: a% increase in life span (% ILs) is expressed as (T/c−1) × 100%, where T is 
the median survival time of treated mice and c is the median survival time of control 
mice; bP values versus control were determined by use of Log-rank test (significant 
variation, P , 0.01);  cP values vs 5-FU were determined by use of Log-rank test 
(significant variation, P , 0.05).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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than that of  188Re-BMEDA. These results suggested that 
pegylated nanolipsomes have higher bioavailability than 
188Re-BMEDA, and the transportation of passive-targeted 
liposomes loaded with  188Re-BMEDA on tumor sites was 
achieved.
In vivo and noninvasive molecular imaging such as 
positron emission tomography (PET), single photon emis-
sion computed tomography (SPECT), magnetic resonance 
imaging, and optical imaging have gradually expanded to 
drug discovery and development in preclinical studies.31–33 
In this study, in vivo direct visualization of tumor and ascites 
targeting and distribution of  188Re-liposomes were evalu-
ated in peritoneal carcinomatosis mice by micro-SPECT/
CT imaging, which provides further information for in vivo 
tumor and ascites retention (Figure 2). The information from 
micro-SPECT/CT imaging is also supported by whole-body 
autoradiography and biodistribution data. An intraperitoneal 
ovarian cancer nude rat model was previously studied with 
in vivo microPET imaging, and the study found that ascites 
gathered from tumor-bearing rats had higher fludeoxyglucose 
uptake than the peritoneal fluid collected from control rats, 
which is similar to the results of the present study.34
Optimized radionuclide therapy for cancer treatment is 
based on the concept of absorbed dose to the dose limiting 
normal organ or tissue, and either red marrow or the liver 
may be the dose-limiting critical organ for radionuclide 
pegylated nanoliposome therapy.35 Macey and Meredith 
projected 188Re as the most advantageous of the β emitters 
for a favorable tumor/marrow ratio.36 In the present authors’ 
dosimetry study, the absorbed doses to liver, red marrow, and 
total body with intravenous injection were 0.24, 0.04, and 
0.11 mSv/MBq for 188Re-liposomes (Table 3), which were 
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lower than those reported by Emfietzoglou et al (of 0.44, 0.12, 
and 0.15 mSv/MBq, respectively), for an 188Re-labeled small 
unilamellar vesicle liposome.19 According to the present 
authors’ dosimetry results, red marrow was regarded as the 
primary critical organ for 188Re-liposomes. This low-absorbed 
dose of red marrow for 188Re-liposomes allows the maximized 
activity of 188Re-liposomes to be administrated for achieving 
the highest absorbed dose to tumors.
Safra et al report that tumor size is an important 
  prognostic factor for therapeutic response to the liposomal 
drug doxorubicin in ovarian cancer, which suggests that the 
tumor volume is clinically relevant for liposome uptake.37 
The trend is that the liposome uptake is higher in smaller 
tumors,38,39 which is consistent with Harrington’s findings 
in animal tumor models.40 The effect of tumor size on the 
tumor-absorbed dose of 188Re-liposomes was also calculated 
using OLINDA|EXM (Table 4). The results showed that the 
tumor-absorbed dose decreased almost ninefold for tumors 
between 1 and 10 g (588 mSv/MBq and 65.7 mSv/MBq, 
repectively) and 85-fold with tumor mass changing from 
1 to 100 g (588 mSv/MBq and 6.91 mSv/MBq, repectively) 
for 188Re-liposomes. These results indicate that small tumors 
could receive a higher absorbed dose than larger tumors and 
reflect one of the advantages of 188Re-liposomes in treating 
peritoneal carcinomatosis with multiple small-volume 
tumor nodules. It is also suggested that 188Re-liposomes 
may have the potential to be applied in adjuvant treatment 
combined with cytoreductive surgery to eliminate residual 
tumor nodules.
Intraperitoneal inoculation of tumor cells in an animal 
model is a commonly used method to induce peritoneal 
carcinomatosis.41 The tumor progressive patterns in the mouse 
model discussed here also mimic the pathological features 
seen in clinical practice, including preferential seeding to 
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Figure 5 The total tumor nodules derived from (A) greater omentum, (B) diaphragm, (C) liver hilum, and (D) mesentery were sampled in the tubes and weighed at 0, 2, 4, 
and 7 days after administration of 188Re-liposomes (29.6 MBq,  ), 5-FU (144 mg/kg, •), and normal saline ( ), respectively, by single intravenous injection. 
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the greater omentum and the development of hemorrhagic 
ascites.3 The authors’ treatments were administered at 7 days 
after tumor inoculation to evaluate the therapeutic efficacy in 
the early stages of peritoneal carcinomatosis. Significantly 
improved therapeutic efficacy of 188Re-liposomes in treating 
peritoneal carcinomatosis was revealed in the present study. 
It was shown that internal radiotherapy with 188Re-liposomes 
achieved the best curative effects, including extended lifespan 
(increase of 34.6%; Table 5), reduced production of ascites 
(decrease of 83.3% at 14 days; Figure 4A), and inhibited 
tumor growth (decrease of 63.4% at 14 days; Figure 4B). 
These results are significantly better than those seen after 
treatment with 5-FU chemotherapy and in the vehicle group 
of normal saline.
It should be noted that significant inhibition of ascites 
formation was observed in the  188Re-liposome-treated 
group for the period of peritoneal metastatic progression 
(Figure 4A). The presentation of ascites in association 
with colonic carcinoma has been attributed to metastases. 
However, the large accumulation of ascites is also 
considered a prominent factor contributing to the large 
incidence of further spread of tumor implants in peritoneal 
cavity.3 Therefore, the management of patients with ascites 
is important, not only for improving quality of life but also 
for restricting metastatic progression.42 Moreover, 188Re-
liposomes exhibited greater antitumor activity than 5-FU 
in all the metastatic sites collected, especially in the liver 
hilum and mesentery (Figure 5C and D). In 188Re-liposome-
treated mice, it was found that most of the tumor nodules 
clustered in the greater omentum, rather than spreading 
to multiple implanted sites as in the 5-FU-treated group. 
These observations suggested that the  188Re-liposome 
treatment is more effective in inhibiting tumor growth 
and further dissemination in peritoneal carcinomatosis 
than 5-FU.
Conclusion
The present study demonstrates the advantages of intrave-
nously administrated 188Re-liposomes in treating peritoneal 
carcinomatosis in a mouse model. The biodistribution, 
pharmacokinetics, and imaging studies of 188Re-liposomes 
in the peritoneal carcinomatosis model revealed good tumor 
and ascites targeting, bioavailability, and localization. 
The dosimetry study also provides safety information 
for  188Re-liposomes in further clinical applications. In a 
therapeutic study,  188Re-liposomes were found to achieve 
apparent curative ability, including inhibition of the tumor 
cell proliferation and further dissemination, and malignant 
ascites formation. The results presented here establish the 
potential of 188Re-liposomes for the treatment of peritoneal 
carcinomatosis.
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